Related Experiment Video

Updated: Apr 6, 2026

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.3K

Targeting c-MYC in Platinum-Resistant Ovarian Cancer

Jeyshka M Reyes-González1, Guillermo N Armaiz-Peña2, Lingegowda S Mangala3

  • 1Department of Biochemistry, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico.

Molecular Cancer Therapeutics
|August 1, 2015
PubMed

Insights

Silencing c-MYC, a protein linked to poor survival in ovarian cancer, significantly reduced tumor growth and improved cell death in cisplatin-resistant models. This suggests c-MYC is a promising therapeutic target for ovarian cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • High c-MYC mRNA levels correlate with decreased disease-free (DFS) and overall survival (OS) in ovarian cancer patients.
  • Elevated c-MYC protein expression is observed in cisplatin-resistant ovarian cancer cell lines compared to sensitive ones.

Purpose of the Study:

  • To investigate the molecular and therapeutic effects of silencing c-MYC using small interfering RNA (siRNA) in cisplatin-resistant ovarian cancer.
  • To evaluate c-MYC as a potential therapeutic target in ovarian cancer.

Main Methods:

  • Analysis of patient data from The Cancer Genome Atlas (TCGA) for survival correlations.
  • In vitro assessment of cell viability, growth, cell-cycle, and apoptosis in ovarian cancer cell lines following c-MYC silencing.
  • In vivo evaluation of therapeutic efficacy using murine xenograft models treated with c-MYC-siRNA encapsulated in nanoliposomes.

Main Results:

  • siRNA-mediated c-MYC silencing led to significant inhibition of cell growth and viability.
  • Depletion of c-MYC induced cell-cycle arrest and promoted apoptosis in resistant ovarian cancer cells.
  • Nanoliposome-formulated c-MYC-siRNA significantly reduced tumor growth in vivo.

Conclusions:

  • c-MYC plays a crucial role in the progression and chemoresistance of ovarian cancer.
  • Targeting c-MYC with siRNA, particularly when delivered via nanoliposomes, demonstrates significant therapeutic potential.
  • c-MYC is identified as a viable therapeutic target for overcoming cisplatin resistance in ovarian cancer.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K